Reply to T. Kurokawa et al

Affiliations

¹ Shveta S. Motwani, Brigham and Women's Hospital; Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA; and Gary C. Curhan, Brigham and Women's Hospital; Channing Division of Network Medicine; and Harvard Medical School, Boston, MA.

Comment

Shveta S Motwani et al. J Clin Oncol. 2018.

. 2018 Aug 10;36(23):2454.

doi: 10.1200/JCO.2018.79.0832. Epub 2018 Jun 29.

¹ Shveta S. Motwani, Brigham and Women's Hospital; Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA; and Gary C. Curhan, Brigham and Women's Hospital; Channing Division of Network Medicine; and Harvard Medical School, Boston, MA.

No abstract available

Comment on

Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin.
Motwani SS, McMahon GM, Humphreys BD, Partridge AH, Waikar SS, Curhan GC. Motwani SS, et al. J Clin Oncol. 2018 Mar 1;36(7):682-688. doi: 10.1200/JCO.2017.75.7161. Epub 2018 Jan 10. J Clin Oncol. 2018. PMID: 29320311 Free PMC article.
Risk Prediction Model for Cisplatin-Associated Acute Kidney Injury.
Kurokawa T, Tsurita G, Tanimoto T, Yamada T, Ferrone S. Kurokawa T, et al. J Clin Oncol. 2018 Aug 10;36(23):2453-2454. doi: 10.1200/JCO.2018.77.8761. Epub 2018 Jun 29. J Clin Oncol. 2018. PMID: 29958036 No abstract available.